MedTrace Logo

GV 1001 Immunotherapy in Patients With Non-small Cell Lung Cancer (NSCLC)

NCT00509457 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2011-07-01

No results posted yet for this study

Summary

To examine the safety and efficacy of telomerase peptide vaccination ( stimulation of the immune system) in patients with NSCLC after having been treated with conventional therapy with radiotherapy and docetaxel as a radiosensitizer.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

BIOLOGICAL

GV 1001 Telomerase peptide

Sponsors & Collaborators

  • St. Olavs Hospital

    collaborator OTHER

  • Sorlandet Hospital HF

    collaborator OTHER_GOV

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Steinar Aamdal · Oslo University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Completion
2009-08-31

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00509457 on ClinicalTrials.gov